Source:http://linkedlifedata.com/resource/pubmed/id/17365274
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2007-3-16
|
pubmed:abstractText |
This study was conducted to investigate the possibility of performing nose-to-brain delivery of TS-002, which is an analog compound of prostaglandin D2 (PGD2) and thus would be a natural sleep inducer. The absolute bioavailability (BA) and sleep-inducing effect (SIE) following intranasal (IN) administration of TS-002 dry powder to cynomolgus monkeys were evaluated in comparison with intravenous (IV) administration. The SIE was evaluated as the accumulated time of sleeping-posture for 3 h. The brain distribution of TS-002 following IN administration of the dry powder was examined in rats. The absolute bioavailability (BA) in monkeys following IN administration of the dry powder (0.4-1.2 mg/body) was comparatively high (43.4-78.0%). The SIE following IN administration (0.05-0.4 mg/body) showed dose-dependency and its effect at 0.4 mg/body was twice as strong as that for IV administration (P < 0.05). The brain concentrations in rats following IN administration (0.1 mg/kg) were obviously higher than that for IV administration at the same dose. The highest content was observed in the olfactory bulb. These results demonstrated that TS-002 was directly transported from the olfactory region to brain, thereby showing that it may be possible to develop a novel sleep-inducing drug based on nose-to-brain delivery.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
1061-186X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
15
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
59-66
|
pubmed:meshHeading |
pubmed-meshheading:17365274-Administration, Intranasal,
pubmed-meshheading:17365274-Animals,
pubmed-meshheading:17365274-Area Under Curve,
pubmed-meshheading:17365274-Biological Availability,
pubmed-meshheading:17365274-Blood-Brain Barrier,
pubmed-meshheading:17365274-Brain,
pubmed-meshheading:17365274-Drug Delivery Systems,
pubmed-meshheading:17365274-Hypnotics and Sedatives,
pubmed-meshheading:17365274-Injections, Intravenous,
pubmed-meshheading:17365274-Macaca fascicularis,
pubmed-meshheading:17365274-Male,
pubmed-meshheading:17365274-Nebulizers and Vaporizers,
pubmed-meshheading:17365274-Powders,
pubmed-meshheading:17365274-Prostaglandin D2,
pubmed-meshheading:17365274-Rats,
pubmed-meshheading:17365274-Rats, Sprague-Dawley,
pubmed-meshheading:17365274-Sleep
|
pubmed:year |
2007
|
pubmed:articleTitle |
Nose-to-brain delivery of TS-002, prostaglandin D2 analogue.
|
pubmed:affiliation |
Research Strategy Division, Taisho Pharmaceutical Co., Ltd., 403, Yoshino-cho 1-chrome, Kita-ku, Saitama-shi, Saitama, 331-9530, Japan. kenji.yamada@po.rd.taisho.co.jp
|
pubmed:publicationType |
Journal Article
|